

REPLY

Serial No. 09/954,586
Atty. Docket No. GP116-03.UTAmendments to the Claims

1. (Currently Amended) A hybridization assay probe comprising an oligonucleotide which a target binding region from 18 to 35 bases in length that hybridizes to a target sequence present in target nucleic acid derived from a *Cryptosporidium parvum* organism in a test sample under stringent conditions to form a probe:target hybrid stable for detection, said oligonucleotide having an at least 10 contiguous base region which is at least 80% complementary to an at least 10 contiguous base region present in the target sequence, wherein the said target sequence is being selected from the group consisting of SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14 and SEQ ID NO:18, wherein said probe does not comprise a base region in addition to said target binding region that is capable of stably binding to said target nucleic acid under said conditions, and wherein said probe does not hybridize to nucleic acid derived from a *Cryptosporidium muris*, *Cryptosporidium baileyi* or *Cryptosporidium Cryptosporidium wrairi* organism in the test sample to form a probe:non-target hybrid stable for detection under the said stringent conditions.

Claims 2-10 (Canceled)

11. (Currently Amended) The probe of claim 1, wherein said probe contains at least two base sequences which regions that hybridize to each other when said probe is not hybridized to the said target sequence under the stringent said conditions.

12. (Currently Amended) The probe of claim 1, wherein said probe comprises one or more at least one base sequences which do region that does not stably hybridize to nucleic acid derived from a *Cryptosporidium parvum* organism, or to nucleic acid derived from a non-target organism present in the test sample, under the stringent said conditions.

REPLY

Serial No. 09/954,586
Atty. Docket No. GP116-03.UT

13. Canceled

14. (Original) The probe of claim 1 further comprising a detectable label.

15. (Currently Amended) The probe of claim + 11 further comprising a group of interacting labels.

16. (Original) The probe of claim 15, wherein said interacting labels include a luminescent label and a quencher label.

17. (Currently Amended) The probe of claim 1, wherein said oligonucleotide target binding region includes at least one ribonucleotide modified to include a 2'-O-methyl substitution to the ribofuranosyl moiety.18. (Currently Amended) The probe of claim 1, wherein a pseudo peptide backbone joins at least a portion of the bases of said oligonucleotide target binding region.19. (Currently Amended) The probe of claim 1, wherein the stringent said conditions comprise 100 mM succinic acid, 2% (w/v) LLS, 15 mM aldrithiol-2, 1.2 M LiCl, 20 mM EDTA, 3% (v/v) ethyl alcohol (absolute), pH 4.7, and a test sample temperature of about 60°C.20. (Currently Amended) A hybridization assay The probe of claim 1, comprising an oligonucleotide which hybridizes to a target sequence present in nucleic acid derived from a *Cryptosporidium parvum* organism in a test sample under stringent conditions to form a probe:target hybrid stable for detection; said oligonucleotide having a wherein the base sequence which of said target binding region is at least 80% complementary to the base sequence of the said target sequence;

REPLY

Serial No. 09/954,586
Atty. Docket No. GP116-03.UT

wherein the target sequence has a base sequence selected from the group consisting of SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14 and SEQ ID NO:18, and wherein said probe does not hybridize to nucleic acid derived from a *Cryptosporidium muris*, *Cryptosporidium baileyi* or *Cryptosporidium wrairi* organism in the test sample to form a probe:non-target hybrid stable for detection under the stringent conditions.

21. (Currently Amended) An oligonucleotide The probe of claim 1, which hybridizes to a target sequence present in nucleic acid derived from a *Cryptosporidium parvum* organism in a test sample under stringent conditions to form a probe:target hybrid stable for detection; wherein the base sequence of said probe is at least 80% complementary to the base sequence of the said target sequence, wherein the target sequence is selected from the group consisting of SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14 and SEQ ID NO:18, and wherein said probe does not hybridize to nucleic acid derived from a *Cryptosporidium muris*, *Cryptosporidium baileyi* or *Cryptosporidium wrairi* organism in the test sample to form a probe:non-target hybrid stable for detection under the stringent conditions.

22. (Currently Amended) An oligonucleotide The probe of claim 1, which hybridizes to a target sequence present in nucleic acid derived from a *Cryptosporidium parvum* organism in a test sample under stringent conditions to form a probe:target hybrid stable for detection; wherein the base sequence of said probe is fully complementary to the base sequence of the said target sequence, wherein the target sequence is selected from the group consisting of SEQ ID NO:6 SEQ ID NO:10, SEQ ID NO:14 and SEQ ID NO:18, and wherein said probe does not hybridize to nucleic acid derived from a *Cryptosporidium muris*, *Cryptosporidium baileyi* or *Cryptosporidium wrairi* organism in the test sample to form a probe:non-target hybrid stable for detection under the stringent conditions.

REPLY

Serial No. 09/954,586
Atty. Docket No. GP116-03.UT

23. (Currently Amended) A probe mix comprising the said probe of claim 1 and a first helper oligonucleotide from 18 to 35 bases in length that hybridizes to having an at least 10 contiguous base region which is at least 80% complementary to an at least 10 contiguous base region present in a target sequence selected from the group consisting of SEQ ID NO:29, SEQ ID NO:33, SEQ ID NO:37 and SEQ ID NO:41 under stringent conditions.

Claims 24-28 (Canceled)

29. (Currently Amended) The probe mix of claim 23 further comprising a second helper oligonucleotide from 18 to 35 bases in length that hybridizes to having an at least 10 contiguous base region which is at least 80% complementary to an at least 10 contiguous base region present in a target sequence selected from the group consisting of SEQ ID NO:32, SEQ ID NO:36, SEQ ID NO:40 and SEQ ID NO:44 under stringent conditions.

Claims 30-36 (Canceled)

37. (Currently Amended) A method for determining the presence of a *Cryptosporidium parvum* organism in a test sample, said method comprising the steps of:

contacting the said test sample with said probe of claim 1 under stringent conditions; and

determining whether a probe:target hybrid has formed under the stringent conditions as an indication of the presence of a *Cryptosporidium parvum* organism in the said test sample.

38. (Currently Amended) The method of claim 37 further comprising providing to the said test sample a first amplification primer oligonucleotide under amplification conditions, said first primer amplification oligonucleotide comprising a target binding region from 18 to 40

REPLY

Serial No. 09/954,586
Atty. Docket No. GP116-03.UT

bases in length that hybridizes to an oligonucleotide having an at least 10 contiguous base region which is at least 80% complementary to an at least 10 contiguous base region present in a target sequence selected from the group consisting of SEQ ID NO:48, SEQ ID NO:54, SEQ ID NO:60 and SEQ ID NO:66 under said amplification conditions, wherein said first amplification oligonucleotide does not comprise a base region in addition to said target binding region that is capable of stably binding to a target nucleic acid containing said target sequence under said amplification conditions, and wherein said primer first amplification oligonucleotide optionally includes a 5' sequence which that is recognized by an RNA polymerase or which that enhances initiation or elongation by an RNA polymerase.

39. (Currently Amended) The method of claim 38 further comprising providing to the said test sample a second amplification primer oligonucleotide under said amplification conditions, said second amplification oligonucleotide comprising a target binding region from 18 to 40 bases in length that hybridizes to an oligonucleotide having an at least 10 contiguous base region which is at least 80% complementary to an at least 10 contiguous base region present in a target sequence selected from the group consisting of SEQ ID NO:45, SEQ ID NO:51, SEQ ID NO:57 and SEQ ID NO:63 under said amplification conditions, wherein said second amplification oligonucleotide does not comprise a base region in addition to said target binding region that is capable of stably binding to a target nucleic acid containing said target sequence under said amplification conditions, and wherein said second amplification oligonucleotide optionally includes a 5' sequence that is recognized by an RNA polymerase or that enhances initiation or elongation by an RNA polymerase.

40. (Currently Amended) The method of claim 38 further comprising providing to the said test sample a second amplification primer oligonucleotide under amplification conditions, said second amplification oligonucleotide comprising a target binding region from 18 to 40 bases

REPLY

Serial No. 09/954,586
Atty. Docket No. GP116-03.UT

in length that hybridizes to an oligonucleotide having an at least 10 contiguous base region which is at least 80% complementary to an at least 10 contiguous base region present in a target sequence selected from the group consisting of SEQ ID NO:46, SEQ ID NO:52, SEQ ID NO:58 and SEQ ID NO:64 under said amplification conditions, wherein said second amplification oligonucleotide does not comprise a base region in addition to said target binding region that is capable of stably binding to a target nucleic acid containing said target sequence under said amplification conditions, and wherein said second amplification oligonucleotide optionally includes a 5' sequence that is recognized by an RNA polymerase or that enhances initiation or elongation by an RNA polymerase

Claims 41-49 (Canceled)

50. (Currently Amended) A method for determining the presence of a *Cryptosporidium parvum* organism in a test sample, said method comprising the steps of:

contacting the said test sample with said probe of claim 20 under stringent conditions; and

determining whether a probe:target hybrid has formed under the stringent conditions as an indication of the presence of a *Cryptosporidium parvum* organism in the said test sample.

51. (Currently Amended) A method for determining the presence of a *Cryptosporidium parvum* organism in a test sample, said method comprising the steps of:

contacting the said test sample with said probe of claim 21 under stringent conditions; and

determining whether a probe:target hybrid has formed under the stringent conditions as an indication of the presence of a *Cryptosporidium parvum* organism in the said test sample.

REPLY

Serial No. 09/954,586
Atty. Docket No. GP116-03.UT

52. (Currently Amended) A method for determining the presence of a *Cryptosporidium parvum* organism in a test sample, said method comprising the steps of:

contacting the said test sample with said probe of claim 22 under stringent conditions; and

determining whether a probe:target hybrid has formed under the stringent conditions as an indication of the presence of a *Cryptosporidium parvum* organism in the said test sample.

53. (Currently Amended) A kit comprising, in packaged combination, first and second oligonucleotides for use in determining the presence of a *Cryptosporidium parvum* organism in a test sample, each of said oligonucleotides having an at least 10 contiguous base region which is at least 80% complementary to an at least 10 contiguous base region present in comprising a target binding region that hybridizes to a target sequence contained present in target nucleic acid derived from a *Cryptosporidium parvum* organism under hybridization conditions, said target binding region of said first oligonucleotide being from 18 to 35 bases in length and said target binding region of said second oligonucleotide being from 18 to 40 bases in length,

wherein: said the target sequence of said first oligonucleotide is selected from the group consisting of SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14 and SEQ ID NO:18;

wherein said the target sequence of said second oligonucleotide is selected from the group consisting of SEQ ID NO:48, SEQ ID NO:54, SEQ ID NO:60 and SEQ ID NO:66;

wherein neither of said first and second oligonucleotides comprises a base region in addition to said target binding region that is capable of stably binding to said target nucleic acid under said conditions, and

wherein said second oligonucleotide optionally includes a 5' sequence which that is recognized by an RNA polymerase or which that enhances initiation or elongation by an RNA polymerase.

REPLY

Serial No. 09/954,586
Atty. Docket No. GP116-03.UT

Claims 54-58 (Canceled)

59. (Currently Amended) The kit of claim 53 further comprising a third oligonucleotide, wherein said third oligonucleotide has an at least 10 contiguous base region which is at least 80% complementary to an at least 10 contiguous base region present in said third oligonucleotide comprising a target binding region from 18 to 40 bases in length that hybridizes to a target sequence contained present in target nucleic acid derived from a *Cryptosporidium parvum* organism under hybridization conditions, and wherein the said target sequence of said third oligonucleotide is being selected from the group consisting of SEQ ID NO:45, SEQ ID NO:51, SEQ ID NO:57 and SEQ ID NO:63, wherein said third oligonucleotide does not comprise a base region in addition to said target binding region that is capable of stably binding to said target nucleic acid under said conditions, and wherein said third oligonucleotide optionally includes a 5' sequence that is recognized by an RNA polymerase or that enhances initiation or elongation by an RNA polymerase.

60. (Currently Amended) The kit of claim 53 further comprising a third oligonucleotide, wherein said third oligonucleotide has an at least 10 contiguous base region which is at least 80% complementary to an at least 10 contiguous base region present in said third oligonucleotide comprising a target binding region from 18 to 40 bases in length that hybridizes to a target sequence contained present in target nucleic acid derived from a *Cryptosporidium parvum* organism under hybridization conditions, and wherein the said target sequence of said third oligonucleotide is being selected from the group consisting of SEQ ID NO:46, SEQ ID NO:52, SEQ ID NO:58 and SEQ ID NO:64, wherein said third oligonucleotide does not comprise a base region in addition to said target binding region that is capable of stably binding to said target nucleic acid under said conditions, and wherein said third oligonucleotide optionally includes a 5' sequence that

REPLY

Serial No. 09/954,586
Atty. Docket No. GP116-03.UT

is recognized by an RNA polymerase or that enhances initiation or elongation by an RNA polymerase.

Claims 61-83 (Canceled)

84. (Currently Amended) A kit comprising, in packaged combination, first and second oligonucleotides for use in determining the presence of a *Cryptosporidium parvum* organism in a test sample, each of said oligonucleotides having an at least 10 contiguous base region which is at least 80% complementary to an at least 10 contiguous base region present in comprising a target binding region from 18 to 35 bases in length that hybridizes to a target sequence contained present in target nucleic acid derived from a *Cryptosporidium parvum* organism under stringent conditions,

wherein: said the target sequence of said first oligonucleotide is selected from the group consisting of SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14 and SEQ ID NO:18, and

wherein said the target sequence of said second oligonucleotide is selected from the group consisting of SEQ ID NO:29, SEQ ID NO:33, SEQ ID NO:37 and SEQ ID NO:41,

wherein neither of said first and second oligonucleotides comprises a base region in addition to said target binding region that is capable of stably binding to said target nucleic acid under said conditions, and

wherein said first oligonucleotide does not hybridize to nucleic acid derived from a *Cryptosporidium muris*, *Cryptosporidium baileyi* or *Cryptosporidium wrairi* organism to form a probe:non-target hybrid stable for detection under said conditions.

Claims 85-86 (Canceled)

87. (Withdrawn) The probe of claim 1, wherein the base sequence of said probe comprises the base sequence of SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13 or SEQ ID NO:17.

REPLY

Serial No. 09/954,586
Atty. Docket No. GP116-03.UT

88. (Withdrawn) The probe of claim 1, wherein the base sequence of said probe consists of or is contained within the base sequence of SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13 or SEQ ID NO:17.

89. (Withdrawn) The probe of claim 1, wherein the base sequence of said probe consists of the base sequence of SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13 or SEQ ID NO:17.

90. (Withdrawn) The probe of claim 1, wherein the base sequence of said probe comprises the base sequence of SEQ ID NO:7, SEQ ID NO:11, SEQ ID NO:15 or SEQ ID NO:19.

91. (Withdrawn) The probe of claim 1, wherein the base sequence of said probe consists of or is contained within the base sequence of SEQ ID NO:7, SEQ ID NO:11, SEQ ID NO:15 or SEQ ID NO:19.

92. (Withdrawn) The probe of claim 1, wherein the base sequence of said probe consists of the base sequence of SEQ ID NO:7, SEQ ID NO:11, SEQ ID NO:15 or SEQ ID NO:19.

93. (Currently Amended) The probe of claim 20, wherein said oligonucleotide has a the base sequence of said target binding region which is 100% fully complementary to the base sequence of the said target sequence.

94. (Currently Amended) A probe mix comprising the said probe of claim 20 and a first helper oligonucleotide up to 35 bases in length and having a base sequence which that is at least 80% complementary to the base sequence of a target sequence selected from the group consisting of SEQ ID NO:29, SEQ ID NO:33, SEQ ID NO:37 and SEQ ID NO:41, wherein said first helper oligonucleotide hybridizes to said target sequence under stringent conditions.

REPLY

Serial No. 09/954,586
Atty. Docket No. GP116-03.UT

95. (Currently Amended) The probe mix of claim 94 further comprising a second helper oligonucleotide up to 35 bases in length and having a base sequence which that is at least 80% complementary to the base sequence of a target sequence selected from the group consisting of SEQ ID NO:32, SEQ ID NO:36, SEQ ID NO:40 and SEQ ID NO:44, wherein said second helper oligonucleotide hybridizes to said target sequence under stringent conditions.

96. (Currently Amended) A probe mix comprising the said probe of claim 21 and a first helper oligonucleotide, wherein the base sequence of said first helper oligonucleotide is at least 80% complementary to the base sequence of a target sequence selected from the group consisting of SEQ ID NO:29, SEQ ID NO:33, SEQ ID NO:37 and SEQ ID NO:41, wherein said first helper oligonucleotide hybridizes to said target sequence under stringent conditions.

97. (Currently Amended) The probe mix of claim 96 further comprising a second helper oligonucleotide, wherein the base sequence of said second helper oligonucleotide is at least 80% complementary to the base sequence of a target sequence selected from the group consisting of SEQ ID NO:32, SEQ ID NO:36, SEQ ID NO:40 and SEQ ID NO:44, wherein said second helper oligonucleotide hybridizes to said target sequence under stringent conditions.

98. (Currently Amended) A probe mix comprising the said probe of claim 22 and a first helper oligonucleotide, wherein the base sequence of said first helper oligonucleotide is fully complementary to the base sequence of a target sequence selected from the group consisting of SEQ ID NO:29, SEQ ID NO:33, SEQ ID NO:37 and SEQ ID NO:41.

REPLY

Serial No. 09/954,586
Atty. Docket No. GP116-03.UT

99. (Currently Amended) The probe mix of claim 98 further comprising a second helper oligonucleotide, wherein the base sequence of said second helper oligonucleotide is fully complementary to the base sequence of a target sequence selected from the group consisting of SEQ ID NO:32, SEQ ID NO:36, SEQ ID NO:40 and SEQ ID NO:44.

100. (Withdrawn) The probe mix of claim 23, wherein the base sequence of said probe comprises the base sequence of SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13 or SEQ ID NO:17.

101. (Withdrawn) The probe mix of claim 23, wherein the base sequence of said probe consists of or is contained within the base sequence of SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13 or SEQ ID NO:17.

102. (Withdrawn) The probe mix of claim 23, wherein the base sequence of said probe consists of the base sequence of SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13 or SEQ ID NO:17.

103. (Withdrawn) The probe mix of claim 23, wherein the base sequence of said probe comprises the base sequence of SEQ ID NO:7, SEQ ID NO:11, SEQ ID NO:15 or SEQ ID NO:19.

104. (Withdrawn) The probe mix of claim 23, wherein the base sequence of said probe consists of or is contained within the base sequence of SEQ ID NO:7, SEQ ID NO:11, SEQ ID NO:15 or SEQ ID NO:19.

REPLY

Serial No. 09/954,586
Arty. Docket No. GP116-03.UT

105. (Withdrawn) The probe mix of claim 23, wherein the base sequence of said probe consists of the base sequence of SEQ ID NO:7, SEQ ID NO:11, SEQ ID NO:15 or SEQ ID NO:19.

106. (Currently Amended) A probe mix comprising the probe of claim 93 and a first helper oligonucleotide up to 35 bases in length and having a base sequence which that is 100% fully complementary to the base sequence of a target sequence selected from the group consisting of SEQ ID NO:29, SEQ ID NO:33, SEQ ID NO:37 and SEQ ID NO:41, wherein said first helper oligonucleotide hybridizes to said target sequence under stringent conditions.

107. (Currently Amended) The probe mix of claim 106 further comprising a second helper oligonucleotide up to 35 bases in length and having a base sequence which that is 100% fully complementary to the base sequence of a target sequence selected from the group consisting of SEQ ID NO:32, SEQ ID NO:36, SEQ ID NO:40 and SEQ ID NO:44, wherein said second helper oligonucleotide hybridizes to said target sequence under stringent conditions.

108. (Withdrawn) The method of claim 37, wherein the base sequence of said probe comprises the base sequence of SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13 or SEQ ID NO:17.

109. (Withdrawn) The method of claim 37, wherein the base sequence of said probe consists of or is contained within the base sequence of SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13 or SEQ ID NO:17.

REPLY

Serial No. 09/954,586
Atty. Docket No. GP116-03.UT

110. (Withdrawn) The method of claim 37, wherein the base sequence of said probe consists of the base sequence of SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13 or SEQ ID NO:17.

111. (Withdrawn) The method of claim 37, wherein the base sequence of said probe comprises the base sequence of SEQ ID NO:7, SEQ ID NO:11, SEQ ID NO:15 or SEQ ID NO:19.

112. (Withdrawn) The method of claim 37, wherein the base sequence of said probe consists of or is contained within the base sequence of SEQ ID NO:7, SEQ ID NO:11, SEQ ID NO:15 or SEQ ID NO:19.

113. (Withdrawn) The method of claim 37, wherein the base sequence of said probe consists of the base sequence of SEQ ID NO:7, SEQ ID NO:11, SEQ ID NO:15 or SEQ ID NO:19.

114. (Currently Amended) The method of claim 50 further comprising providing to the said test sample a first amplification primer oligonucleotide under amplification conditions, said first primer amplification oligonucleotide comprising a target binding region from 18 to 40 bases in length that hybridizes to an oligonucleotide having a base sequence a target sequence which is at least 80% complementary to a base sequence selected from the group consisting of SEQ ID NO:48, SEQ ID NO:54, SEQ ID NO:60 and SEQ ID NO:66 under said amplification conditions, wherein said first amplification oligonucleotide does not comprise a base region in addition to said target binding region that is capable of stably binding to a target nucleic acid containing said target

REPLY

Serial No. 09/954,586
Atty. Docket No. GP116-03.UT

sequence under said amplification conditions, and wherein said primer first amplification oligonucleotide optionally includes a 5' sequence which that is recognized by an RNA polymerase or which that enhances initiation or elongation by an RNA polymerase.

115. (Currently Amended) The method of claim 114 further comprising providing to the said test sample a second amplification primer oligonucleotide under said amplification conditions, said second amplification oligonucleotide comprising a target binding region from 18 to 40 bases in length that hybridizes to an oligonucleotide having a base sequence a target sequence which is at least 80% complementary to a base sequence selected from the group consisting of SEQ ID NO:45, SEQ ID NO:51, SEQ ID NO:57 and SEQ ID NO:63 under said amplification conditions, wherein said second amplification oligonucleotide does not comprise a base region in addition to said target binding region that is capable of stably binding to a target nucleic acid containing said target sequence under said amplification conditions, and wherein said second amplification oligonucleotide optionally includes a 5' sequence that is recognized by an RNA polymerase or that enhances initiation or elongation by an RNA polymerase.

116. (Currently Amended) The method of claim 114 further comprising providing to the said test sample a second amplification primer oligonucleotide under said amplification conditions, said second amplification oligonucleotide comprising a target binding region from 18 to 40 bases in length that hybridizes to an oligonucleotide having a base sequence a target sequence which is at least 80% complementary to a base sequence selected from the group consisting of SEQ ID NO:46, SEQ ID NO:52, SEQ ID NO:58 and SEQ ID NO:64 under said amplification conditions, wherein said second amplification oligonucleotide does not comprise a base region in addition to said target binding region that is capable of stably binding to a target nucleic acid containing said

REPLY

Serial No. 09/954,586
Atty. Docket No. GP116-03.UT

target sequence under said amplification conditions, and wherein said second amplification oligonucleotide optionally includes a 5' sequence that is recognized by an RNA polymerase or that enhances initiation or elongation by an RNA polymerase.

117. (Currently Amended) The method of claim 50, wherein said oligonucleotide has a the base sequence which of said target binding region is 100% fully complementary to the base sequence of the said target sequence.

118. (Currently Amended) The method of claim 117 further comprising providing to the said test sample a first amplification primer oligonucleotide comprising a target binding region under amplification conditions, wherein the base sequence of said said first primer comprising target binding region an oligonucleotide having a base sequence which is 100% fully complementary to a the base sequence of a target sequence selected from the group consisting of SEQ ID NO:48, SEQ ID NO:54, SEQ ID NO:60 and SEQ ID NO:66,

wherein said target binding region hybridizes to said target sequence under said amplification conditions.

wherein said first amplification oligonucleotide does not comprise a base region in addition to said target binding region that is capable of stably binding to a target nucleic acid containing said target sequence under said amplification conditions, and

wherein said primer first amplification oligonucleotide optionally includes a 5' sequence which that is recognized by an RNA polymerase or which that enhances initiation or elongation by an RNA polymerase.

119. (Currently Amended) The method of claim 118 further comprising providing to the said test sample a second amplification primer comprising oligonucleotide comprising a target binding region under said amplification conditions, wherein the base sequence of said target binding

REPLY

Serial No. 09/954,586
Atty. Docket No. GP116-03.UT

region an oligonucleotide having a base sequence which is 100% fully complementary to a the base sequence of a target sequence selected from the group consisting of SEQ ID NO:45, SEQ ID NO:51, SEQ ID NO:57 and SEQ ID NO:63,

wherein said target binding region hybridizes to said target sequence under said amplification conditions.

wherein said second amplification oligonucleotide does not comprise a base region in addition to said target binding region that is capable of stably binding to a target nucleic acid containing said target sequence under said amplification conditions, and

wherein said second amplification oligonucleotide optionally includes a 5' sequence that is recognized by an RNA polymerase or that enhances initiation or elongation by an RNA polymerase.

120. (Currently Amended) The method of claim 118 further comprising providing to the said test sample a second amplification primer comprising oligonucleotide comprising a target binding region under said amplification conditions, wherein the base sequence of said target binding region an oligonucleotide having a base sequence which is 100% fully complementary to a the base sequence of a target sequence selected from the group consisting of SEQ ID NO:46, SEQ ID NO:52, SEQ ID NO:58 and SEQ ID NO:64,

wherein said target binding region hybridizes to said target sequence under said amplification conditions.

wherein said second amplification oligonucleotide does not comprise a base region in addition to said target binding region that is capable of stably binding to a target nucleic acid containing said target sequence under said amplification conditions, and

wherein said second amplification oligonucleotide optionally includes a 5' sequence that is recognized by an RNA polymerase or that enhances initiation or elongation by an RNA polymerase.

REPLY

Serial No. 09/954,586
Atty. Docket No. GP116-03.UT

121. (Currently Amended) The method of claim 51 further comprising providing to the said test sample a first amplification primer oligonucleotide comprising a target binding region under amplification conditions, wherein the base sequence of said first primer target binding region is at least 80% complementary to a the base sequence of a target sequence selected from the group consisting of SEQ ID NO:48, SEQ ID NO:54, SEQ ID NO:60 and SEQ ID NO:66,

wherein said target binding region hybridizes to said target sequence under said amplification conditions,

wherein said first amplification oligonucleotide does not comprise a base region in addition to said target binding region that is capable of stably binding to a target nucleic acid containing said target sequence under said amplification conditions, and

wherein said primer first amplification oligonucleotide optionally includes a 5' sequence which that is recognized by an RNA polymerase or which that enhances initiation or elongation by an RNA polymerase.

122. (Currently Amended) The method of claim 121 further comprising providing to the said test sample a second amplification primer oligonucleotide comprising a target binding region under amplification conditions, wherein the base sequence of said second primer target binding region is at least 80% complementary to a the base sequence of a target sequence selected from the group consisting of SEQ ID NO:45, SEQ ID NO:51, SEQ ID NO:57 and SEQ ID NO:63,

wherein said target binding region hybridizes to said target sequence under said amplification conditions,

wherein said second amplification oligonucleotide does not comprise a base region in addition to said target binding region that is capable of stably binding to a target nucleic acid containing said target sequence under said amplification conditions, and

REPLY

Serial No. 09/954,586
Atty. Docket No. GP116-03.UT

wherein said second amplification oligonucleotide optionally includes a 5' sequence that is recognized by an RNA polymerase or that enhances initiation or elongation by an RNA polymerase.

123. (Currently Amended) The method of claim 121 further comprising providing to the said test sample a second amplification primer oligonucleotide comprising a target binding region under amplification conditions, wherein the base sequence of said second primer target binding region is at least 80% complementary to a the base sequence of a target sequence selected from the group consisting of SEQ ID NO:46, SEQ ID NO:52, SEQ ID NO:58 and SEQ ID NO:64,

wherein said target binding region hybridizes to said target sequence under said amplification conditions.

wherein said second amplification oligonucleotide does not comprise a base region in addition to said target binding region that is capable of stably binding to a target nucleic acid containing said target sequence under said amplification conditions, and

wherein said second amplification oligonucleotide optionally includes a 5' sequence that is recognized by an RNA polymerase or that enhances initiation or elongation by an RNA polymerase.

124. (Currently Amended) The method of claim 52 further comprising providing to the said test sample a first amplification primer oligonucleotide comprising a target binding region under amplification conditions, wherein the base sequence of said first primer target binding region is fully complementary to a the base sequence of a target sequence selected from the group consisting of SEQ ID NO:48, SEQ ID NO:54, SEQ ID NO:60 and SEQ ID NO:66,

wherein said target binding region hybridizes to said target sequence under said amplification conditions.

REPLY

Serial No. 09/954,586
Atty. Docket No. GP116-03.UT

wherein said first amplification oligonucleotide does not comprise a base region in addition to said target binding region that is capable of stably binding to a target nucleic acid containing said target sequence under said amplification conditions, and

wherein said primer first amplification oligonucleotide optionally includes a 5' sequence which that is recognized by an RNA polymerase or which that enhances initiation or elongation by an RNA polymerase.

125. (Currently Amended) The method of claim 124 further comprising providing to the said test sample a second amplification primer oligonucleotide comprising a target binding region under amplification conditions, wherein the base sequence of said target binding region second primer is fully complementary to a the base sequence of a target sequence selected from the group consisting of SEQ ID NO:45, SEQ ID NO:51, SEQ ID NO:57 and SEQ ID NO:63,

wherein said target binding region hybridizes to said target sequence under said amplification conditions.

wherein said second amplification oligonucleotide does not comprise a base region in addition to said target binding region that is capable of stably binding to a target nucleic acid containing said target sequence under said amplification conditions, and

wherein said second amplification oligonucleotide optionally includes a 5' sequence that is recognized by an RNA polymerase or that enhances initiation or elongation by an RNA polymerase.

126. (Currently Amended) The method of claim 124 further comprising providing to the said test sample a second amplification primer oligonucleotide comprising a target binding region under amplification conditions, wherein the base sequence of said target binding region second primer is fully complementary to a the base sequence of a target sequence selected from the group consisting of SEQ ID NO:46, SEQ ID NO:52, SEQ ID NO:58 and SEQ ID NO:64,

REPLY

Serial No. 09/954,586
Atty. Docket No. GP116-03.UT

wherein said target binding region hybridizes to said target sequence under said amplification conditions,

wherein said second amplification oligonucleotide does not comprise a base region in addition to said target binding region that is capable of stably binding to a target nucleic acid containing said target sequence under said amplification conditions, and

wherein said second amplification oligonucleotide optionally includes a 5' sequence that is recognized by an RNA polymerase or that enhances initiation or elongation by an RNA polymerase.

127. (Withdrawn) The kit of claim 53, wherein the base sequence of said first oligonucleotide comprises the base sequence of SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13 or SEQ ID NO:17.

128. (Withdrawn) The kit of claim 53, wherein the base sequence of said first oligonucleotide consists of or is contained within the base sequence of SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13 or SEQ ID NO:17.

129. (Withdrawn) The kit of claim 53, wherein the base sequence of said first oligonucleotide consists of the base sequence of SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13 or SEQ ID NO:17.

130. (Withdrawn) The kit of claim 53, wherein the base sequence of said first oligonucleotide comprises the base sequence of SEQ ID NO:7, SEQ ID NO:11, SEQ ID NO:15 or SEQ ID NO:19.

REPLY

Serial No. 09/954,586
Atty. Docket No. GP116-03.UT

131. (Withdrawn) The kit of claim 53, wherein the base sequence of said first oligonucleotide consists of or is contained within the base sequence of SEQ ID NO:7, SEQ ID NO:11, SEQ ID NO:15 or SEQ ID NO:19.

132. (Withdrawn) The kit of claim 53, wherein the base sequence of said first oligonucleotide consists of the base sequence of SEQ ID NO:7, SEQ ID NO:11, SEQ ID NO:15 or SEQ ID NO:19.

133. (Currently Amended) The kit of claim 53, wherein the base sequence of said target binding region of each of said oligonucleotides has a base region which oligonucleotide is at least 80% complementary to the base sequence of the said target sequence of said oligonucleotide.

134. (Currently Amended) The kit of claim 53, wherein the base sequence of each said target binding region of each of said oligonucleotides has a base region which oligonucleotide is 100% fully complementary to the base sequence of the said target sequence of said oligonucleotide.

135. (Currently Amended) The kit of claim 53, wherein the base sequence of each of said oligonucleotide oligonucleotides is at least 80% complementary to the base sequence of the said target sequence of said oligonucleotide.

136. (Currently Amended) The kit of claim 53, wherein the base sequence of each of said oligonucleotide oligonucleotides is fully complementary to the base sequence of the said target sequence of said oligonucleotide.

REPLY

Serial No. 09/954,586
Atty. Docket No. GP116-03.UT

137. (Currently Amended) The kit of claim 59, wherein the base sequence of said target binding region of each of said oligonucleotides has a base region which oligonucleotide is at least 80% complementary to the base sequence of the said target sequence of said oligonucleotide.

138. (Currently Amended) The kit of claim 59, wherein the base sequence of said target binding region of each of said oligonucleotides has a base region which oligonucleotide is 100% fully complementary to the base sequence of the said target sequence of said oligonucleotide.

139. (Currently Amended) The kit of claim 59, wherein the base sequence of each of said oligonucleotide oligonucleotides is at least 80% complementary to the base sequence of the said target sequence of said oligonucleotide.

140. (Currently Amended) The kit of claim 59, wherein the base sequence of each of said oligonucleotide oligonucleotides is fully complementary to the base sequence of the said target sequence of said oligonucleotide.

141. (Currently Amended) The kit of claim 60, wherein the base sequence of said target binding region of each of said oligonucleotides has a base region which oligonucleotide is at least 80% complementary to the base sequence of the said target sequence of said oligonucleotide.

142. (Currently Amended) The kit of claim 60, wherein the base sequence of said target binding region of each of said oligonucleotides has a base region which oligonucleotide is 100% fully complementary to the base sequence of the said target sequence of said oligonucleotide.

REPLY

Serial No. 09/954,586
Atty. Docket No. GP116-03.UT

143. (Currently Amended) The kit of claim 60, wherein the base sequence of each of said oligonucleotides oligonucleotide is at least 80% complementary to the base sequence of the said target sequence of said oligonucleotide.

144. (Currently Amended) The kit of claim 60, wherein the base sequence of each of said oligonucleotides oligonucleotide is fully complementary to the base sequence of the said target sequence of said oligonucleotide.

145. (Withdrawn) The kit of claim 84, wherein the base sequence of said first oligonucleotide comprises the base sequence of SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13 or SEQ ID NO:17.

146. (Withdrawn) The kit of claim 84, wherein the base sequence of said first oligonucleotide consists of or is contained within the base sequence of SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13 or SEQ ID NO:17.

147. (Withdrawn) The kit of claim 84, wherein the base sequence of said first oligonucleotide consists of the base sequence of SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13 or SEQ ID NO:17.

148. (Withdrawn) The kit of claim 84, wherein the base sequence of said first oligonucleotide comprises the base sequence of SEQ ID NO:7, SEQ ID NO:11, SEQ ID NO:15 or SEQ ID NO:19.

REPLY

Serial No. 09/954,586
Atty. Docket No. GP116-03.UT

149. (Withdrawn) The kit of claim 84, wherein the base sequence of said first oligonucleotide consists of or is contained within the base sequence of SEQ ID NO:7, SEQ ID NO:11, SEQ ID NO:15 or SEQ ID NO:19.

150. (Withdrawn) The kit of claim 84, wherein the base sequence of said first oligonucleotide consists of the base sequence of SEQ ID NO:7, SEQ ID NO:11, SEQ ID NO:15 or SEQ ID NO:19.

151. (Currently Amended) The kit of claim 84, wherein the base sequence of said target binding region of each of said oligonucleotides has a base region which oligonucleotide is at least 80% complementary to the base sequence of the said target sequence of said oligonucleotide.

152. (Currently Amended) The kit of claim 84, wherein the base sequence of said target binding region of each of said oligonucleotides has a base region which oligonucleotide is 100% fully complementary to the base sequence of the said target sequence of said oligonucleotide.

153. (Currently Amended) The kit of claim 84, wherein the base sequence of each of said oligonucleotide oligonucleotides is at least 80% complementary to the base sequence of the said target sequence of said oligonucleotide.

154. (Currently Amended) The kit of claim 84, wherein the base sequence of each of said oligonucleotide oligonucleotides is fully complementary to the base sequence of the said target sequence of said oligonucleotide.

155. (Currently Amended) The kit of claim 84 further comprising a third oligonucleotide comprising a target binding region from 18 to 35 bases in length that hybridizes to;

REPLY

Serial No. 09/954,586
Atty. Docket No. GP116-03.UT

wherein said third oligonucleotide has an at least 10 contiguous base region which is at least 80% complementary to an at least 10 contiguous base region present in a target sequence contained present in target nucleic acid derived from a *Cryptosporidium parvum* organism under stringent conditions, and wherein the said target sequence of said third oligonucleotide is being selected from the group consisting of SEQ ID NO:32, SEQ ID NO:36, SEQ ID NO:40 and SEQ ID NO:44.

156. (Currently Amended) The kit of claim 155, wherein each of said oligonucleotide oligonucleotides has a base region which that is at least 80% complementary to the base sequence of the said target sequence of said oligonucleotide.

157. (Currently Amended) The kit of claim 155, wherein each of said oligonucleotide oligonucleotides has a base region which that is 100% fully complementary to the base sequence of the said target sequence of said oligonucleotide.

158. (Currently Amended) The kit of claim 155, wherein the base sequence of each of said oligonucleotide oligonucleotides is at least 80% complementary to the base sequence of the said target sequence of said oligonucleotide.

159. (Currently Amended) The kit of claim 155, wherein the base sequence of each of said oligonucleotide oligonucleotides is fully complementary to the base sequence of the said target sequence of said oligonucleotide.